Directed carbapenemase testing is no longer just for Enterobacterales: cost, labor, and workflow assessment of expanding carbapenemase testing to carbapenem-resistant P. aeruginosa

References

• van Duin D, Arias CA, Komarow L, et al. Multi-drug resistant organism network investigators. molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study. Lancet Infect Dis. 2020;20:731–741. doi:10.1016/S1473-3099(19)30755-8.
   PubMed Web of Science ®Google Scholar
• Tamma PD, Goodman KE, Harris AD, et al. Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant enterobacteriaceae bacteremia. Clin Infect Dis. 2017;64:257–264. doi:10.1093/cid/ciw741.
   PubMed Web of Science ®Google Scholar
• Falcone M, Bassetti M, Tiseo G, et al. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae. Crit Care. 2020;24:29. doi:10.1186/s13054-020-2742-9.
   PubMed Web of Science ®Google Scholar
• Satlin MJ, Chen L, Gomez-Simmonds A, et al. Impact of a rapid molecular test for Klebsiella pneumoniae carbapenemase and ceftazidime-avibactam use on outcomes after bacteremia caused by carbapenem-resistant enterobacterales. Clin Infect Dis. 2022: ciac354. doi:10.1093/cid/ciac354.
   Web of Science ®Google Scholar
• Karlsson M, Lutgring JD, Ansari U, et al. Molecular characterization of carbapenem-resistant enterobacterales collected in the United States. Microb Drug Resist. 2022;28:389–397. doi:10.1089/mdr.2021.0106.
   PubMed Web of Science ®Google Scholar
• Gill CM, Aktas E, Alfouzan W, et al. Nicolau DP; ERACE-PA global study group. The ERACE-PA global surveillance program: ceftolozane/tazobactam and ceftazidime/avibactam in vitro activity against a global collection of carbapenem-resistant Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 2021;40:2533–2541. doi:10.1007/s10096-021-04308-0.
   PubMed Web of Science ®Google Scholar
• Lucena A, Dalla Costa LM, Nogueira KS, et al. Nosocomial infections with metallo-beta-lactamase-producing pseudomonas aeruginosa: molecular epidemiology, risk factors, clinical features and outcomes. J Hosp Infect. 2014;87:234–240. doi:10.1016/j.jhin.2014.05.007.
   PubMed Web of Science ®Google Scholar
• Walters MS, Grass JE, Bulens SN, et al. Carbapenem-resistant Pseudomonas aeruginosa at US emerging infections program sites, 2015. Emerg Infect Dis. 2019;25:1281–1288.
   PubMed Web of Science ®Google Scholar
• Tenover FC, Nicolau DP, Gill CM. Carbapenemase-producing Pseudomonas aeruginosa -an emerging challenge. Emerg Microbes Infect. 2022;11:811–814. doi:10.1080/22221751.2022.2048972.
   PubMed Web of Science ®Google Scholar
• CLSI. Performance standards for antimicrobial susceptibility testing— Thirty-second Edition: M100. 2022.
   Google Scholar
• Tamma PD, Aitken SL, Bonomo RA, et al. Infectious diseases society of America guidance on the treatment of extended-spectrum β-lactamase producing enterobacterales (ESBL-E), carbapenem-resistant enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021;72:e169–e183.
   PubMedGoogle Scholar
• Reyes S, Nicolau DP. Precision medicine for the diagnosis and treatment of carbapenem-resistant enterobacterales: time to think from a different perspective. Expert Rev Anti Infect Ther. 2020;18:721–740. doi:10.1080/14787210.2020.1760844.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. CDC’s Antimicrobial Resistance (AR) Laboratory Networks. https://www.cdc.gov/drugresistance/laboratories.html. Accessed 27 September 2022.
   Google Scholar
• Banerjee R, Humphries R. Clinical and laboratory considerations for the rapid detection of carbapenem-resistant enterobacteriaceae. Virulence. 2017;8:427–439. doi:10.1080/21505594.2016.1185577.
   PubMed Web of Science ®Google Scholar
• Lutgring JD, Limbago BM. The problem of carbapenemase-producing-carbapenem-resistant-enterobacteriaceae detection. J Clin Microbiol. 2016;54:529–534. doi:10.1128/JCM.02771-15.
   PubMed Web of Science ®Google Scholar
• Gill CM, Asempa TE, Nicolau DP. Development and application of a pragmatic algorithm to guide definitive carbapenemase testing to identify carbapenemase-producing Pseudomonas aeruginosa. Antibiotics (Basel). 2020;9:738, doi:10.3390/antibiotics9110738.
   PubMed Web of Science ®Google Scholar
• Gill CM, Aktas E, Alfouzan W, et al. Prospective validation of a phenotypic algorithm to guide carbapenemase testing in carbapenem-resistant Pseudomonas aeruginosa using the ERACE-PA global surveillance program. Open Forum Infect Dis. 2021;9:ofab617, doi:10.1093/ofid/ofab617.
   PubMed Web of Science ®Google Scholar
• Gill CM, Kresken M, Seifert H, et al. Evaluation of a phenotypic algorithm to direct carbapenemase testing in Pseudomonas aeruginosa: validation in a multicenter German cohort. Microb Drug Resist. 2021;27:1243–1248. doi:10.1089/mdr.2020.0476.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Labor. Labor statistics. https://www.bls.gov/oes/current/oes191022.htm. (Accessed 15 Sept 2022).
   Google Scholar
• Roth JA, Hornung-Winter C, Radicke I, et al. Direct costs of a contact isolation day: a prospective cost analysis at a Swiss university hospital. Infect Control Hosp Epidemiol. 2018;39:101–103.
   PubMed Web of Science ®Google Scholar
• Hernando K, Waite L, Bairagdar N, et al. A waterfall of susceptibility results: impact of microbiology testing cascade for MDROs. Diagn Microbiol Infect Dis. 2022;104:115731, doi:10.1016/j.diagmicrobio.2022.115731.
   PubMed Web of Science ®Google Scholar
• Gill CM, Asempa TE, Tickler IA, et al. Evaluation of the Xpert Carba-R NxG assay for detection of carbapenemase genes in a global challenge set of Pseudomonas aeruginosa isolates. J Clin Microbiol. 2020;58:e01098–20. doi:10.1128/JCM.01098-20.
   PubMed Web of Science ®Google Scholar
• Khan A, Tran TT, Rios R, et al. Extensively drug-resistant pseudomonas aeruginosa ST309 harboring tandem guiana extended spectrum β-lactamase enzymes: a newly emerging threat in the United States. Open Forum Infect Dis. 2019;6:ofz273, doi:10.1093/ofid/ofz273.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Clinicians: Information about CRE. https://www.cdc.gov/hai/organisms/cre/cre-clinicians.html. Accessed 27 September 2022.
   Google Scholar
• Centers for Disease Control and Prevention. Pseudomonas aeruginosa in Healthcare Settings. https://www.cdc.gov/hai/organisms/pseudomonas.html#CDC. Accessed 27 September 2022.
   Google Scholar
• Centers for Disease Control and Prevention. Interim Guidance for a Public Health Response to Contain Novel or Targeted Multidrug-resistant Organisms (MDROs). https://www.cdc.gov/hai/pdfs/containment/Health-Response-Contain-MDRO-H.pdf Accessed 9 December 2022.
   Google Scholar
• Nagao M, Iinuma Y, Igawa J, et al. Control of an outbreak of carbapenem-resistant Pseudomonas aeruginosa in a haemato-oncology unit. J Hosp Infect. 2011;79:49–53.
   PubMed Web of Science ®Google Scholar
• Knoester M, de Boer MG, Maarleveld JJ, et al. An integrated approach to control a prolonged outbreak of multidrug-resistant Pseudomonas aeruginosa in an intensive care unit. Clin Microbiol Infect. 2014;20:O207–O215.
   PubMed Web of Science ®Google Scholar
• Suarez C, Peña C, Arch O, et al. A large sustained endemic outbreak of multiresistant Pseudomonas aeruginosa: a new epidemiological scenario for nosocomial acquisition. BMC Infect Dis. 2011;11:272.
   PubMed Web of Science ®Google Scholar
• Mehrotra P, Croft L, Day HR, et al. Effects of contact precautions on patient perception of care and satisfaction: a prospective cohort study. Infect Control Hosp Epidemiol. 2013;34:1087–1093. doi:10.1086/673143.
   PubMed Web of Science ®Google Scholar
• Berneking L, Both A, Berinson B, et al. Performance of the BD Phoenix CPO detect assay for detection and classification of carbapenemase-producing organisms. Eur J Clin Microbiol Infect Dis. 2021;40:979–985. doi:10.1007/s10096-020-04094-1.
   PubMed Web of Science ®Google Scholar
• Croxatto A, Coste AT, Pillonel T, et al. Evaluation of the BD Phoenix™ CPO detect test for the detection of carbapenemase producers. Clin Microbiol Infect. 2020;26(644):e9–e15. doi:10.1016/j.cmi.2019.10.002.
   Google Scholar
• Whitley V, Kircher S, Gill T, et al. Multicenter evaluation of the BD Phoenix CPO detect test for detection and classification of carbapenemase-producing organisms in clinical isolates. J Clin Microbiol. 2020;58:e01752–19.
   PubMed Web of Science ®Google Scholar
• Gill CM, Lasko MJ, Asempa TE, et al. Evaluation of the EDTA-modified carbapenem inactivation method for detecting metallo-β-lactamase-producing Pseudomonas aeruginosa. J Clin Microbiol. 2020;58:e02015–19.
   PubMed Web of Science ®Google Scholar
• Lisboa LF, Turnbull L, Boyd DA, et al. Evaluation of a modified carbapenem inactivation method for detection of carbapenemases in Pseudomonas aeruginosa. J Clin Microbiol. 2017;56:e01234–17. doi:10.1128/JCM.01234-17.
   PubMed Web of Science ®Google Scholar
• Ferjani S, Maamar E, Ferjani A, et al. Evaluation of three carbapenemase-phenotypic detection methods and emergence of diverse VIM and GES variants among Pseudomonas aeruginosa isolates in Tunisia. Antibiotics (Basel). 2022;11:858, doi:10.3390/antibiotics11070858.
   PubMed Web of Science ®Google Scholar
• Traczewski MM, Carretto E, Canton R, et al. Multicenter evaluation of the xpert carba-R assay for detection of carbapenemase genes in gram-negative isolates. J Clin Microbiol. 2018;56:e00272–18. doi:10.1128/JCM.00272-18.
   PubMed Web of Science ®Google Scholar